Posted on

NeonMind Announces DTC Eligibility

NeonMind Announces DTC Eligibility

Vancouver, B.C. – August 25, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FFE: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today that its common shares listed on the OTCQB under the symbol “NMDBF” are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC“) in the United States.

The DTC is a subsidiary of the Depository Trust & Clearing Corporation that manages the electronic clearing and settlement of publicly traded companies in the United States. Securities that are eligible to be electronically cleared and settled through DTC are considered to be “DTC eligible.” The electronic method of clearing securities through the DTC allows for cost-effective clearing and guaranteed settlement, simplifying and accelerating the settlement process for investors trading the Company’s shares.

“By receiving DTC eligibility, NeonMind’s common shares are more accessible to a broader range of potential investors,” said Rob Tessarolo, President and CEO of NeonMind. “Being DTC eligible simplifies the process of transferring the Company’s shares between brokerages in the United States and speeds up the execution of trades, which should help to increase the liquidity of our stock. This is an important step as we continue to advance our business efforts and broaden awareness for our company in both domestic and international markets.”

 

About NeonMind Biosciences Inc.

NeonMind is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. The Company operates three divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings; and (iii) a consumer products division that currently sells mushroom-infused products to promote health and wellness.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

NeonMind’s consumer division currently sells NeonMind-branded coffee products in the United States and Canada through NeonMind’s direct to consumer e-commerce platform.

For more information on NeonMind, go to www.NeonMindBiosciences.com.

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.

rob@neonmind.com

Tel: 416-750-3101

 

Investor Relations:

KCSA Strategic Communications

Scott Eckstein/Tim Regan

neonmind@kcsa.com

Tel: 212-896-1210

 

Media Inquiries:

KCSA Strategic Communications
Annie Graf

neonmind@kcsa.com

Tel: 786-390-2644

 

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

Posted on

Delic Announces Ben Westhoff, Award-Winning Investigative Reporter Specializing in Fentanyl to Speak at Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Meet Delic, a revolutionary, two-day immersive edutainment experience for the world’s leading psychedelic and wellness thought and business leaders will take place at AREA15 in Las Vegas, Nevada, November 6 – 7, 2021

Vancouver, BC, August 24, 2021 – Delic Holdings Corp. (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that Ben Westhoff will serve as one of the headline speakers at Meet Delic the world’s premiere psychedelic and wellness edutainment event catering to both curious newcomers, business and thought leaders.

Ben Westhoff is an award-winning investigative reporter who writes about culture, drugs, and poverty. His book Fentanyl, Inc.: How Rogue Chemists Created the Deadliest Wave of the Opioid Epidemic is the bombshell first book about the fentanyl epidemic, and he has advised officials at the top levels of government about the crisis. His previous book Original Gangstas is the definitive work on N.W.A., Tupac, and West Coast hip-hop. He came up in the alternative weeklies Riverfront Times and L.A. Weekly and has also written for The Atlantic, The Wall Street Journal, Rolling Stone, and the Guardian.

“I’ve spoken at conferences around the country, but have never been so excited as this one,” said Westhoff. “I hope to see you there!”

Westhoff ‘s keynote appearance, Fentanyl in our Drugs, will discuss how fentanyl isn’t just a problem for heroin users but how it is upending the entire recreational drug landscape. His presentation will show how fentanyl affects drug legalization prospects, dark web markets, geopolitics, and much more, and whether there’s any hope for ending the opioid crisis.

“Ben’s thought provoking journalism has exposed serious problems with the way we fight drug abuse and opens up the possibility of better treatment with far fewer side effects,” said Delic co-founder, Jackee Stang. “His objective take on the realm of treatments will be incredibly interesting and educational for the Meet Delic audience.”

Meet Delic will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.

          ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. DELIC is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com

Posted on

Lobe Sciences Appoints Albert “Skip” Rizzo, Ph.D to Scientific Advisory Board

Lobe Sciences Appoints Albert “Skip” Rizzo, Ph.D to Scientific Advisory Board

Director, Medical Virtual Reality – Institute for Creative Technologies
Research Professor – Dept. of Psychiatry and School of Gerontology
University of Southern California

Vancouver, British Columbia–(Newsfile Corp. – August 23, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to announce the appointment of Albert “Skip” Rizzo, Ph.D, to its Scientific Advisory Board.

Philip Young, CEO and Director of Lobe stated, “We are extremely happy to have an industry leading Virtual Reality (VR) expert joining our Scientific Advisory Board, and look forward to his contributions on our clinical development and the creation of our Krysalis Therapeutic Pod.”

Albert “Skip” Rizzois a clinical psychologist and Director of Medical VR at the University of Southern California Institute for Creative Technologies. He is also a Research Professor with the USC Dept. of Psychiatry and School of Gerontology. Over the last 25 years, Skip has conducted research on the design, development and evaluation of Virtual Reality systems targeting the areas of clinical assessment, treatment, and rehabilitation across the domains of psychological, cognitive and motor functioning in both healthy and clinical populations. This work has focused on PTSD, TBI, Autism, ADHD, Alzheimer’s disease, stroke and other clinical conditions. He has also driven an extensive research program on the use of intelligent virtual human agents for clinical training, healthcare information support, and clinical assessment. In spite of the diversity of these clinical R&D areas, the common thread that drives all of his work with digital technologies involves the study of how Virtual Reality simulations can be usefully applied to human healthcare beyond what’s possible with traditional 20th Century methods.

Albert “Skip” Rizzo, Ph.D stated, “I look forward to working with an exceptional SAB as we seek to make Lobe’s treatments available to the millions of patients suffering from TBI and PTSD. I have spent the majority of my career investigating the integration of Virtual Reality (VR) and am now exploring the use of VR as a tool for enhancing the efficacy of psychedelic therapy. The science in both of these areas is promising and the merger of these approaches may add value for some patients as they seek relief from debilitating mental health conditions. I look forward to continuing this work as we jointly develop the Krysalis Pod as a method to support the delivery of VR in this therapeutic context.”

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, progression with nasal mist device engineering and commercialization, the pursuit of M&A initiatives, development of effective delivery methods and commercialization potential of the nasal mist device, research and development using NAC and psilocybin and growth of the business, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; and that the current Board and management may not be able to attain the Company’s corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Posted on

Silo Wellness Announces $3 Million U.S. Sales and Distribution Partnership for Marley One Line of Functional Mushrooms

Silo Wellness Announces $3 Million U.S. Sales and Distribution Partnership for Marley One Line of Functional Mushrooms

TORONTO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness” or the “Company”) (CSE: SILO) (OTCQB: SILFF) (FRA: 3K70), a leading global psychedelics company, today announced a $3 million national distribution agreement with Texas-based distribution and advertising company One Light Enterprises LLC. (“One Light”) for Silo Wellness’ portfolio of Marley One branded mushroom products across 47 U.S. states (the “Distribution Agreement”).

Today’s announcement comes on the heels of Silo Wellness’ U.K. distribution agreement with LocoSoco Group PLC, announced earlier this month. Together with the Distribution Agreement, Silo Wellness has cemented strong routes to market in both the U.S. and the U.K. for its Marley One global mushroom brand, created in collaboration with the family of legendary musician Bob Marley.

“We have seen tremendous consumer interest in the Marley One brand, and we are pleased to announce a distribution partner for the all-important U.S. market,” said Douglas K. Gordon, Chief Executive Officer, Silo Wellness. “One Light is a respected and like-minded partner who shares our vision for Marley One and our commitment to delivering best-in-class consumer experiences and products.”

One Light will distribute the full line of Marley One mushroom products, beginning with the brand’s initial five functional mushroom tinctures, to retailers across the U.S. Silo Wellness also intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules, and cosmetics.

“We are excited to partner with Silo Wellness to bring Marley One to U.S. consumers,” said Twin Rivers Group, LLC, Managing Member of One Light. “We partner with some of the best-loved brands in the market today, and we anticipate Marley One will be well-received by consumers, particularly as they seek out natural, plant-based wellness products to enhance their everyday lives.”

According to Mordor Intelligence, the global functional mushroom market was valued at USD 25,415.12 million in 2020, and is estimated to register a CAGR of 8.44% during the forecast period of 2021-2026. Mordor Intelligence also notes that functional mushrooms are expected to have increased applicability beyond healthcare or pharmaceutical products over the long term, particularly in the food and beverage sector.

Corporate Update

On August 11, 2021, the Company entered into a loan agreement with an arm’s length third party lender (the “Lender”) pursuant to which the Company borrowed US$250,000 for working capital and inventory growth purposes (the “Loan”). Subsequently, the Company entered into a debt settlement agreement with the Lender to settle US$144,000 of the Loan in exchange for 2,500,000 Common Shares at a deemed price of C$0.072 per Common Share, representing a 20% discount to the closing price of the Common Shares on August 11, 2021 (the “Shares for Debt”). The remaining principal amount of the Loan remains outstanding. Completion of the Shares for Debt is subject to compliance with applicable regulations, including policies of the CSE.

The Company has agreed to issue Common Shares to two arm’s length service providers in accordance with previously agreed arrangements (the “Shares for Services”). Pursuant to various agreement for services, the Company intends to issue an aggregate of 5,310,000 Common Shares with 5,000,000 Common Shares issued at a deemed price of C$0.13 and 310,000 Common Shares issued at a deemed price of C$0.10. Completion of the Shares for Services is subject to compliance with applicable regulations, including policies of the CSE.

The Company also announces that Peter Holzworth, vice president of business development has resigned from his position.

For more information about Silo Wellness, please visit https://www.silowellness.com/. To buy Marley One products, please visit https://marleyone.com/.

ABOUT SILO WELLNESS 
Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 and headquartered in Toronto, Silo Wellness has operations in Jamaica and Oregon. Silo Wellness is a publicly-traded company on the Canadian (CSE: SILO) and Frankfurt (FRA: CK70) exchanges and trading on the OTCQB Venture Market (OTCQB: SILFF).

Silo Wellness offers a diverse and growing portfolio of functional mushroom products, psychedelic wellness retreats in Jamaica and Oregon, cultivation of psychedelic mushrooms and truffles in Jamaica, development of a brick-and-mortar smart shop in Jamaica, and intellectual property, focused initially on the commercialization of its metered-dosing psilocybin nasal spray.

In March 2021, Silo Wellness announced a multi-year licensing agreement with the family of legendary musician Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. The Marley One line of functional mushrooms is available at www.marley.one.

For more information about Silo Wellness, please visit www.silowellness.com.

For further information, please contact:

Silo Wellness Media Relations:
hello@trailblaze.co

Silo Wellness Investor Relations:
(778) 383-6740
ir@silowellness.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements”  (collectively, “forward-looking statements”) within the meaning of the applicable Canadian  securities legislation. All statements, other than statements of historical fact, are forward-looking  statements and are based on expectations, estimates, and projections as at the date of this news  release. Any statement that involves discussions with respect to predictions, expectations, beliefs,  plans, projections, objectives, assumptions, future events or performance (often but not always  using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not  anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or  variations of such words and phrases or stating that certain actions, events or results “may” or  “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical  fact and may be forward-looking statements. In this news release, forward-looking statements  relate, among other things, to: the Distribution Agreement the distribution partnership with One Light, the Shares for Debt, the Shares for Services and the business plans of Silo Wellness. Forward-looking statements are  necessarily based upon a number of estimates and assumptions that, while considered  reasonable, are subject to known and unknown risks, uncertainties, and other factors which may  cause the actual results and future events to differ materially from those expressed or implied by  such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19.  There can be no assurance that such statements will prove to be accurate, as actual results and  future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on the forward-looking statements and information  contained in this news release. Silo Wellness assumes no obligation to update the forward-looking  statements of beliefs, opinions, projections, or other factors, should they change, except as  required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES  PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS  RELEASE. 

Posted on

Psyence Group announces the commencement of online sales and distribution of “GOODMIND™” products

Toronto, Canada/, Cape Town August 18, 2021 – Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce the commencement of online sales and distribution of its premium range of functional mushroom products, GOODMIND™.  The GOODMIND™ formulas harness the power of adaptogens; non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits.  GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.

Psyence has partnered with Goodleaf, a leading wellness and lifestyle brand with a premium range of products infused with African botanicals. Their products exist to enhance emotional wellbeing through inspiring acts of self-care, routine and habit that can enhance quality of life, every day. Goodleaf has demonstrated great competence in launching new consumer goods in an emerging industry. Psyence is experienced in product development, scientific research, procurement, manufacturing, and logistics.  Both companies intend to leverage their knowledge and experience in the nutraceutical and supplement industry to create class-leading products in the functional mushroom space.

Neil Maresky, Chief Executive Officer, Psyence Group Inc. says: “We are delighted that our first nutraceutical product, GOODMIND™, is now available for sale online in South Africa. This is an important milestone for Psyence as we look to grow our over-the-counter nutraceutical wellness collection. Goodleaf has a proven track record of successfully launching and distributing high-quality products and we believe they are an excellent partner to successfully launch GOODMIND™ in this growing market.”

“Our experience in developing and launching new consumer products will be invaluable as we make headway in the functional mushroom space. There is no doubt that there is a growing demand for wellness products, and we are extremely excited to collaborate with Psyence, as we launch GOODMIND™ and bring a range of functional mushroom products to market,” says Warren Schewitz, Founder and Chief Executive Officer of Goodleaf.

GOODMIND™ will begin online sales starting August 18, 2021.  For more information on GOODMIND™, visit the website: https://foragoodmind.com/

ABOUT PSYENCE GROUP: https://psyence.com

Psyence, a public life science biotechnology company listed on the Canadian Securities Exchange (CSE: PSYG), sets the global standard for natural psychedelics. Psyence leads the way in natural psilocybin and other psychedelics for the healing of psychological trauma and its mental health consequences in the context of palliative care. Our name “Psyence” combines the words psychedelic and science to affirm our commitment to producing psychedelic medicines developed through evidence-based research.

Informed by nature and guided by science, we built and operate one of the world’s first federally licensed commercial psilocybin mushroom cultivation and production facilities. Our team brings international experience in both business and science and includes experts in mycology, neurology, and drug development.  We work to develop advanced psilocybin products and other psychedelic breakthroughs for research institutes, clinics, therapeutic immersions, and destination experiences for clinical research. We are also developing a nutraceutical mental wellness collection that supports improved focus, calm, and sleep.

Our four key divisions (Psyence Production, Psyence Therapeutics, Psyence Function, and Psyence Experience) anchor an international footprint with operations in Canada, United States, United Kingdom, Jamaica, South Africa, and Australia.

ABOUT GOODLEAF: https://goodleaf.co.za

Goodleaf is Africa’s leading CBD wellness and lifestyle brand with a premium range of 26 products infused with African botanicals. Their products are specifically targeted towards enhancing emotional well-being through inspiring acts of self care, routine and habit that can enhance quality of life, every day.

Their product offering includes oils, skincare topicals, CBD infused sparkling drinks, natural vapes and powder sachets. Goodleaf products are available in South Africa from their three retail stores, their own online store as well as from leading brands such as Woolworths, Superbalist, Wellness Warehouse, Vida e Caffè and Poetry. CBD beverages are available at over 1,000 outlets across South Africa including Spar, Pick ‘n Pay, Checkers and Clicks. Goodleaf products will soon be available in the UK in selected UK stores as well as Amazon UK.

Contact Information:

Lisa-Marie Iannitelli, Investor Relations
Email: ir@psyence.com

Media Inquiries: media@psyence.com

General Information: info@psyence.com

Certain statements in this news release related to Psyence Group Inc and its subsidiaries (collectively “the Company”) are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the perceived size and profitability of the functional mushroom market, the demand for wellness products, the ability of the Company to leverage Goodleaf’s existing distribution networks and the obtaining of all such licences, registrations and consents as may be required from regulatory and governmental authorities regulating complementary medicines and health supplements. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

Posted on

OPTIMI HEALTH CLEARS FINAL BASE SHELF PROSPECTUS

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC (GLOBE NEWSWIRE – August 18, 2021) – Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that it has filed and received a final receipt for a short form base shelf prospectus (the “Final Shelf Prospectus“) with the securities commissions in each of the provinces and territories of Canada, except Québec.

The Final Shelf Prospectus allows the Company to offer and issue up to $100,000,000 of common shares, warrants, subscription receipts, units, or any combination of such securities (collectively, the “Securities“) during the 25-month period that the Final Shelf Prospectus is effective. The Securities may be offered separately or together, in amounts, at prices and on terms to be determined based on market conditions at the time of sale, which will be set forth in any one or more prospectus supplement(s) filed in connection with any such distribution(s).

Optimi CEO, Mike Stier, stated, “while the Company has no immediate intention to undertake an offering, this Final Shelf Prospectus allows the Company to maintain financial flexibility as we advance our business objectives and goals.”

The Securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Securities in any State or jurisdiction in which such offer, solicitation or sale would be unlawful.

A copy of the Final Shelf Prospectus is available under the Company’s profile on SEDAR (www.sedar.com).

On Behalf of the Board of Directors

Optimi Health Corp.

Mike Stier
President, Chief Executive Officer and Director

ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:

Investor Relations

Email: investors@optimihealth.ca

Phone: +1 (778) 930-1321

Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS

This news release contains forward-looking statements, including regarding the development of the Company’s business, potential distributions pursuant to the Final Shelf Prospectus and the filing of one or more prospectus supplements. These forward-looking statements are provided as of the date of this news release, and reflect predictions, expectations or beliefs regarding future events based information currently available to the Company. In making the forward-looking statements included in this news release, the Company has applied several material assumptions, including, but not limited to, the assumption that required approvals of any distribution proposed under the Final Shelf Prospectus and any supplement thereto will be obtained in a timely manner; that general economic and business conditions will not change in a materially adverse manner; and that the Company will be able to raise funds on reasonable terms. Although management considers these assumptions to be reasonable based on information available to them, they may prove to be incorrect. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions on which they are based do not reflect future experience. We caution readers not to place undue reliance on these forward-looking statements as a number of important factors could cause the actual outcomes to differ materially from the expectations expressed in them. These risk factors may be generally stated as the risk that the assumptions and estimates expressed above do not occur, but specifically include, without limitation, risks relating to: general market conditions; the Company’s ability to secure financing, on favourable terms, pursuant to the Final Shelf Prospectus and any prospectus supplements; and the additional risks described in the Final Shelf Prospectus and the Company’s Annual Information Form, and other disclosure documents filed by the Company on SEDAR. The foregoing list of factors that may affect future results is not exhaustive. When relying on our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company does not undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by the Company or on behalf of the Company, except as required by law.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

 

Posted on

NeonMind Receives Health Canada Approval For Its Functional Mushroom Formulation ‘Mindful Blend’

Vancouver, B.C. – August 17, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FFE: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today that Health Canada has approved its application for Product License NPN 80111611, the ‘Mindful Blend’ functional mushroom product.  Mindful Blend uses 100% plant-based extracts and is formulated to support memory and cognitive function, support the immune system, increase energy, combat stress, and reduce inflammation.

Natural Health Products (NHP) require and undergo rigorous review by Health Canada’s Natural Health Product Directorate (NHPD) to ensure the safety and efficacy of the product. NeonMind’s consumer products do not contain any psychoactive or restricted substances.

“The approval from Health Canada allows us to market the proven benefits of our functional mushroom ingredients, differentiating the NeonMind brand as we introduce additional products across the U.S. and Canada. Our consumer products division allows NeonMind to further our reach into the massive functional food market. We continue to meet our strategic operational timelines while also supporting our research and development initiatives,” said Rob Tessarolo, President and CEO of NeonMind.

NeonMind’s consumer products division includes four dietary supplements in the United States designed to support memory, cognitive function and relieve stress, four mushroom infused coffees in Canada and three additional functional mushroom formulas under NHP review with Health Canada.

According to Data Bridge Market Research, the global Medicinal Mushroom market is expected to reach US$78.7 billion by 2025, from US$38.1 billion in 2017 growing at a CAGR of 9.5% during the forecasted period of 2018 to 2025.

In addition to its consumer products division, NeonMind’s pharmaceutical division is engaged in the research and development of drugs and treatments for obesity and obesity related diseases using psychedelic compounds.

About NeonMind Biosciences Inc.

NeonMind is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. The Company operates three divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings; and (iii) a consumer products division that currently sells mushroom-infused products to promote health and wellness.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

NeonMind’s consumer division currently sells NeonMind-branded coffee products in the United States and Canada through NeonMind’s direct to consumer e-commerce platform.

 

For more information on NeonMind, go to www.NeonMindBiosciences.com.

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.

rob@neonmind.com

Tel: 416-750-3101

 

Investor Relations:

KCSA Strategic Communications

Scott Eckstein/Tim Regan

neonmind@kcsa.com

Tel: 212-896-1210

 

Media Inquiries:

KCSA Strategic Communications
Annie Graf

neonmind@kcsa.com

Tel: 786-390-2644

 

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

Posted on

Delic Announces Laura Dawn, Msc., Host of the Psychedelic Leadership Podcast, Business Consultant & Microdosing Mentor to Appear at Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Vancouver, BC, August 17, 2021 – Delic Holdings Inc. (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has announced that Laura Dawn, Msc. will serve as one of the headlining speakers at Meet Delic on November 6th;  catering to both curious newcomers, business and thought leaders. Her keynote, “Exploring the Intersection Between Psychedelics & Creative Problem Solving” targets business and thought-leaders, entrepreneurs, and creators.

“I am honored to be a part of Meet Delic this year, which I believe is a pivotal step in shifting society toward greater acceptance of the benefits of psychedelics for overall wellness,” said Laura Dawn, “I look forward to sharing what I have learned with business and thought-leaders, entrepreneurs, and creators on how to mindfully explore psychedelics and sacred plant medicines as powerful visionary tools for inner transformation and creative manifestation.”

Host of The Psychedelic Leadership Podcast, Laura Dawn, Msc. is a microdosing mentor for executives, and has been leading transformational retreats for over ten years. Through her signature programs and retreats, Dawn weaves together science with wisdom to teach business and thought-leaders, entrepreneurs, and creators how to mindfully explore psychedelics and sacred plant medicines as powerful visionary tools for inner transformation and creative manifestation. Through mindset and somatic coaching, she inspires people to truly expand the boundaries of what they believe is possible and embark on the path of heart-centered leadership to influence meaningful change.

Laura Dawn has a degree in Finance and Entrepreneurship and over two decades of exploring altered states of consciousness. Currently, she is completing a Masters in Science specializing in Creativity Studies & Change Leadership, exploring the intersection between psychedelics and creative problem-solving to help corporate teams unlock innovative solutions to the complex challenges we face.

“Laura Dawn is well-known among the business leaders and entrepreneurial circuits for helping share the benefits of psychedelics in personal and professional development and is exactly the voice we look to highlight at Meet Delic,” said Meet Delic Co-Found and Executive Producer,  Jackee Stang. “Her coaching, life experience and expertise will help today and tomorrow’s leaders in their own careers and lives.”

In addition to her solo appearance, Dawn will lead a panel titled, ‘Microdosing’ alongside Psychable.com ’s CEO: Jemie Sae Koo, Flow State Worldwide’s CEO: Adam Bramlage, and Phoebe McPherson, the Co-Founder of Hearthstone Collective.

The experiential event will feature dancers, music, 3D-mapping, visual artists, new technologies and research, thought-provoking presentations and one of the world’s largest psychedelic business expo.

The twenty hours of panels and keynotes will include anarray of topics such as: “Psychedelics and Sobriety: The Next Frontier in Recovery.” “Why Are Psychedelics Medicine?” “Ketamine Clinics Today, Psilocybin and MDMA Therapy Tomorrow,” “PTSD Reset and Recovery,” “Aphrodisiacs and Psychedelics: A History of Medicine for Love,”“Psychedelic Activism”, “Drug Use for Grown-Ups,” and much more! Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, www.meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

          ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of

this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and DELIC does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com

Posted on

BETTER PLANT’S JUSU LAUNCHES PURE ESSENTIAL OILS AND SPRITZERS

Vancouver, B.C. – August 17, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”), a wellness company that develops and sells sustainable, plant-based products that are better for health and better for the earth, is relaunching a line of ten 100% pure essential oils, and six pure essential oil blends with six essential oil spritzers. These new products will be relaunched as part of the Jusu Wellness Home collection, and are available for purchase in Canada from getjusu.com.

The six essential oils blends and six accompanying spritzers have been relaunched under the names: Cleanse, Wellness, OM, Camper’s Friend, Inspire, and Relax. The pure essential oils come in the varieties: lavender, eucalyptus, grapefruit, peppermint, tea tree, cedarwood, frankincense, ylang ylang, lemon, and bergamot. In keeping with Better Plant’s commitment to doing better for the environment; the glass essential oil bottles and the spritzer bottles are 100% recyclable.

“Jusu Wellness products already contain essential oils due to their beneficial properties for the skin, as well as for their all-natural scents”, says Joelle Fiorito, Director of Operations at Jusu. “Adding essential oils and spritzers allows consumers to bring all of those benefits in to their daily lives, whether is it by adding a few drops of the Relax essential oil blend to a diffuser in their home, or carrying a Camper’s Blend spritzer with them on their next outdoor excursion.”

According to a report by Grandview Research, the global essential oils market demand was estimated at 247.08 kilotons in 2020 and is expected to grow at a compound annual growth rate of 7.5% from 2020 to 2027. Essential oils offer several health benefits, which drives the demand for these oils in pharmaceutical applications. Essential oils are sourced from plants and unlike most of the conventional medicines and drugs, essential oils have no major side effects. Consumers’ rising preference for natural and organic products is driving the application of essential oils in cosmetics, homecare products, and food & beverages.

 

About Better Plant:

Better Plant harnesses plant intelligence and leverages modern science to offer sustainable, plant-based products that are better for health and better for the earth. It makes and sells over 90 proprietary products, all made with 100% natural ingredients, under the brands Jusu, Urban Juve and Wright & Well. Better Plant operates Jusu Bar, a quick serve restaurant alternative in Victoria, BC, which serves up fresh, healthy, and nutritious options with a focus on Jusu cold-pressed juices. Jusubar.com offers home delivery of refrigerated plant-based beverages consisting of cold-pressed juices and packaged juice cleanses for delivery in select cities in Alberta and BC. Through its Shopify enabled eCommerce sites getjusu.com and urbanjuve.com, Better Plant sells plant-based personal care products, including skin care, hair care and body care as well as plant-based all-natural home cleaning products. Better Plant’s products are sold wholesale to retailers, grocers, restaurants and cleaning companies in Canada. Better Plant also offers operational, financial, and other services to companies with businesses that align with Better Plant’s mission to help create a better world. Better Plant incubated NeonMind Biosciences Inc., which sells medicinal mushroom infused coffees and is engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity. Better Plant owns approximately 27% of NeonMind Biosciences Inc., whose common shares trade under the tickers CSE: NEON, OTCQB: NMDBF and FFE: 6UF.

 

For more information on Jusu Wellness, visit getjusu.com or follow Jusu Wellness on Instagram or Facebook.

 

For more information on Better Plant, visit betterplantsciences.com or follow on Instagram, Twitter or LinkedIn.

 

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

 

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com

1-833-515-2677

 

Sales Inquiries:

Amber Allen, Head of Sales

amber@betterplantsciences.com

604-808-8118

 

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

Mydecine Innovations finishes 2Q with C$7M in cash after busy research period pinpoints four new lead drug candidates

CEO Joshua Bartach told investors the company made “groundbreaking progress” and discoveries in its psilocybin compound research and drug development program
Mydecine Innovations Group Inc -

The firm’s net loss for the period narrowed to C$3.8 million

Mydecine Innovations Group Inc (OTC:MYCOF, FRA:0NFA, NEO:MYCO) reported its 2Q results showing the psychedelic firm ended the three-month period with C$7 million in cash and equivalents following a robust research program.

The Denver, Colorado-based company said it had identified four new lead drug candidates in its portfolio and discovered more than 40 potential pharmacologically active novel compounds in mushrooms.

CEO Joshua Bartach told investors that the company made “groundbreaking progress” and discoveries in its psilocybin compound research and drug development program during the three-month period to end June 30, 2021.

READ: Mydecine Innovations Group expands patent portfolio to include MDMA-like compounds

“We identified our four novel lead drug candidates in preparation for Pre-Investigational New Drug Application (Pre-IND) meetings with the US Food and Drug Administration (FDA) and Health Canada. As well as discovering over 40 potential pharmacologically active novel compounds in mushrooms, demonstrating the continued success of our integrated research and cultivation facilities as we build today’s most advanced and extensive portfolio of psychedelic-assisted therapeutics,” Bartach said in a statement.

Outside the drug discovery program, Mydecine also boosted its technology offering with the release of Mindleap 2.0, an upgraded version of its digital health platform to support the adoption of psychedelics into mental health and inner wellness.

Bartach highlighted that and other developments in his review of the quarter.

“We have also significantly leveraged our partnerships with research institutions to drive the evolution of the drug discovery process and partnered with the University of Alberta to initiate a next-generation AI-assisted drug discovery program,” the CEO said.

“We are focused on expanding into more technological end-to-end treatments and launched Mindleap 2.0 in July to support the widespread adoption and normalization of psychedelic-based integration with mental health. Our recent milestones exhibit revolutionary potential with layering applications of first and second-generation therapeutics.”

The firm’s net loss for the period narrowed to C$3.8 million or $0.02 loss per share from the $4.6 million loss or $0.05 loss per share in the same year-ago quarter.

Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import and export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. It also operates out of a state-of-the-art mycology lab in Denver to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.